Recent regulatory scrutiny in Germany has cast a spotlight on misoprostol (Angusta) and its role in labour induction, raising significant safety concerns. As this conversation unfolds across Europe, healthcare professionals are re-evaluating their induction protocols and looking to non-pharmacological methods like DILAPAN-S as a safer alternative.

Your Quarterly Update on Innovations in Women’s Health Welcome to the July 2025 edition of AGHeadlines , where we share the latest...

When a patient presents with abnormal uterine bleeding, particularly during or after menopause, one of the first concerns clinicians must...